Injection of cGAS-NP, a liposomal STING inducer, in preclinical BC models resistant to anti-PD-L1 immunotherapy showed a strong increase in IFNβ expression and secretion, as well as STING/interferon α/β receptor (IFNAR)-pathway-dependent tumor regression [112]. The gene discussed is STING1; the disease is breast cancer.